Literature DB >> 29177592

Hyperandrogenemia and ovarian reserve in patients with Mayer-Rokitansky-Küster-Hauser syndrome type 1 and 2: potential influences on ovarian stimulation.

Melanie Henes1, Ludmila Jurow2, Andreas Peter3, Birgitt Schoenfisch2, Florin Andrei Taran1, Markus Huebner1, Harald Seeger2, Sara Yvonne Brucker1,2, Kristin Katharina Rall4.   

Abstract

PURPOSE: This study aimed to analyze the hormone profiles, to detect the rate of hyperandrogenemia and to investigate the potential effect of Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) on ovarian reserve, as reflected by the serum Anti-Mullerian hormone (AMH) levels. Clinical implications were analyzed by including our own experiences with three patients after ovarian stimulation in preparation for uterus transplantation.
METHODS: Serum samples of 100 patients with MRKHS (50 patients with MRKHS type 1 and 50 with type 2) were analyzed and compared to 50 individually age-matched healthy controls. Blood samples for hormone analyses were collected routinely during the clinical visit.
RESULTS: The mean age was 20.0 years for MRKHS type 1, MRKHS type 2 and healthy controls. Compared to healthy controls, there was no significant difference in AMH values in the MRKH patients. As shown in previous studies, the proportion of hyperandrogenemia without clinical symptoms was significantly higher in MRKHS type 1 (52%; p < 0.001) and type 2 (56%; p < 0.001) patients when compared to age-matched controls. In preparation for uterus transplantation, three patients were stimulated with FSH/hMG for mean 14.2 days and the mean number of aspirated oocytes was 13.2 (3-22), while 8.3 (2-10) oocytes could be fertilized and cryopreserved. The mean fertilization rate was 51.2% (30-67%).
CONCLUSION: The rate of hyperandrogenemia was significantly higher in MRKH patients compared to healthy age-matched controls. Though, ovarian reserve (AMH level) was not reduced compared to controls. Future studies are needed to identify optimal ovarian stimulation protocols as well as to implement a systematic multicenter reporting system.

Entities:  

Keywords:  AMH; Hyperandrogenemia; Mayer–Rokitansky–Küster–Hauser syndrome; Ovarian reserve; Testosterone

Mesh:

Substances:

Year:  2017        PMID: 29177592     DOI: 10.1007/s00404-017-4596-1

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  Precocious puberty or growth hormone deficiency as initial presentation in Mayer-Rokitansky-kuster-Hauser syndrome: a clinical report of 5 cases.

Authors:  Zhuanzhuan Ai; Xiaoyun Zhu; Hong Chen; Ruimin Chen
Journal:  BMC Pediatr       Date:  2022-07-14       Impact factor: 2.567

2.  Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-Küster-Hauser Syndrome: Insight into the Role of Hormones in HS.

Authors:  Angelo Ruggiero; Gabriella Fabbrocini; Matteo Megna; Giuseppe Monfrecola; Claudio Marasca
Journal:  Skin Appendage Disord       Date:  2020-10-19

Review 3.  The evolving role of genetic tests in reproductive medicine.

Authors:  Federica Cariati; Valeria D'Argenio; Rossella Tomaiuolo
Journal:  J Transl Med       Date:  2019-08-14       Impact factor: 5.531

4.  Midgestation origins of androgenic and estrogenic pathophysiology in three major women's health disorders.

Authors:  David H Abbott; Daniel A Dumesic
Journal:  Fertil Steril       Date:  2020-09-10       Impact factor: 7.490

Review 5.  Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update.

Authors:  Morten Krogh Herlin; Michael Bjørn Petersen; Mats Brännström
Journal:  Orphanet J Rare Dis       Date:  2020-08-20       Impact factor: 4.123

6.  Comparison of Androgen Levels, Endocrine and Metabolic Indices, and Clinical Findings in Women with Polycystic Ovary Syndrome in Uygur and Han Ethnic Groups from Xinjiang Province in China.

Authors:  Hongli Zhao; Xiangxin Song; Li Zhang; Yancheng Xu; Xinling Wang
Journal:  Med Sci Monit       Date:  2018-09-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.